{"filings":[{"id":860757,"accession_number":"0001104659-26-070494","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-06-04T20:01:13+00:00","items":["5.07"],"status":"ready","headline":"Aclaris shareholders elect directors, approve executive pay at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["80.55% of shares voted; 112,499,671 of 139,663,680 outstanding shares represented.","Elected Anand Mehra and Maxine Gowen as directors with 83.1M and 84.2M votes for, respectively.","Advisory vote on named executive officer compensation approved: 83.4M for, 9.7M against.","Ratification of PricewaterhouseCoopers as auditor passed with 112.3M votes for.","Broker non-votes of 19.4M on proposals 1 and 2; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93618,"accession_number":"0001104659-26-056669","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q1 net loss widens to $19.8M; positive Phase 1a data for ATI-052","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.8M vs $15.1M YoY; revenue $2.0M (+33%) on higher Lilly/Sun Pharma royalties.","Cash & equivalents $190.8M (up from $151.4M); raised $59.8M via 18.4M share ATM offering in March.","ATI-052 Phase 1a SAD/MAD showed half-life ~45 days, sustained target engagement up to 20 wks; supports Q3-month dosing.","Phase 1b POC trials in asthma and atopic dermatitis ongoing; top line results expected H2 2026.","Completed enrollment in bosakitug Phase 2 AD trial; results expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":1996000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93617,"accession_number":"0001104659-26-049733","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aclaris reports positive Phase 1a data for ATI-052 (half-life ~45 days) and picks lichen planus for ATI-2138","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATI-052 half-life ~45 days; complete inhibition of CCL17/TARC sustained at least 20 weeks post-dose.","Phase 1a ATI-052 well tolerated; no conjunctivitis or safety signals; dose proportional PK observed.","Phase 1b trials in asthma and atopic dermatitis enrolling; top line results expected H2 2026.","Phase 2b for ATI-052 targeting asthma planned for Q4 2026; Phase 2b ATI-2138 in lichen planus starts H2 2026.","ATI-2138 is a potential first-in-class oral ITK/JAK3 inhibitor addressing pathogenic T cells; no FDA-approved LP therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105397,"accession_number":"0001104659-26-026407","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Aclaris Therapeutics sells 5.7M shares for $20M gross proceeds in ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5.7M shares sold on March 10, 2026 for aggregate gross proceeds of $20.0M.","Purchasers include Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP.","Sale under amended sales agreement with Leerink Partners and Cantor Fitzgerald dated Feb 27, 2025.","Gross proceeds of $20M implies average price per share of approximately $3.51."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105396,"accession_number":"0001104659-26-025420","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Aclaris Therapeutics raises $39.8M via ATM offering of 12.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 12.7 million shares for gross proceeds of $39.8M under ATM agreement from March 2-9, 2026.","Shares purchased by institutional investors including Deep Track Capital.","Sales executed by agents Leerink Partners and Cantor Fitzgerald."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105395,"accession_number":"0001104659-26-020070","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q4 net loss $19.8M; cash $151.4M; ATI-052 POC trials underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.8M in Q4 2025 vs $96.6M in Q4 2024; full year net loss $64.9M vs $132.1M.","Total revenue $1.3M in Q4 2025 vs $9.2M prior year; decrease due to 2024 Lilly milestone.","Cash, equivalents and marketable securities $151.4M as of Dec 31, 2025; cash runway into H2 2028.","Interim Phase 1a data for anti-TSLP/IL-4Rα bispecific ATI-052 support rapid advancement; Phase 1b POC trials in AD and asthma initiated.","IND filing for lead ITK inhibitor ATI-9494 expected H2 2026; ATI-2138 showed hair regrowth in alopecia model."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":7826000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105394,"accession_number":"0001104659-26-002694","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics files 8-K furnishing updated corporate overview; no new financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed Form 8-K on Jan. 12, 2026, updating its corporate overview presentation (Exhibit 99.1).","Presentation available on company website; no specific financial or operational changes provided in filing.","No earnings, guidance, clinical results, or other material events disclosed in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105393,"accession_number":"0001104659-26-001076","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Aclaris ATI-052 Phase 1a shows favorable safety, 26-day half-life, near-complete target inhibition at low doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATI-052 well tolerated up to 720 mg; no serious AEs, no discontinuations, mild injection site redness.","PK profile shows at least 26-day effective half-life with dose-proportional Cmax and AUC.","At 30 mg, robust concentration-dependent inhibition of IL-4 and TSLP stimulated CCL17/TARC.","Data supports potential for up to every-3-month dosing; Phase 1b in AD and asthma to start Q1 2026.","Phase 2b in atopic dermatitis planned for H2 2026; top-line data from Phase 1b expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121678,"accession_number":"0001104659-25-107353","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Therapeutics Q3 net loss widens to $14.6M; cash $167.2M; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M in Q3 2025 vs $7.6M in Q3 2024; total revenue $3.3M vs $4.3M.","Cash, equivalents and marketable securities $167.2M as of Sep 30, 2025, funding into H2 2028.","Positive Phase 2a results for ATI-2138 in AD; Phase 2 trial in additional indication expected H1 2026.","Top line results for bosakitug (Phase 2 AD) expected H2 2026; ATI-052 Phase 1b POC in asthma/AD expected H1 2026.","R&D expenses rose to $13.0M (vs $6.0M) driven by clinical and preclinical activities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":6531000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121677,"accession_number":"0001104659-25-098991","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris holds R&D Day presenting I&I pipeline; no specific data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["R&D Day held Oct 14, 2025, focusing on immunology and inflammation (I&I) therapeutic franchises.","Presentation furnished as Exhibit 99.1; available on Investor Relations section of company website.","No financial results, clinical data, or guidance changes were included in the 8-K or exhibit snippet.","Company continues to develop pipeline for gaps in I&I diseases; no material updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138357,"accession_number":"0001558370-25-010640","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q2 net loss widens to $15.4M; advances ATI-2138, bosakitug, ATI-052 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.4M vs $11.0M YoY; revenue $1.8M, down 36% due to prior royalty sale.","Cash, equivalents & securities $180.9M; runway into H2 2028 without new financing.","Phase 2a ATI-2138 met primary/key secondary endpoints; confirms tolerability in moderate-to-severe AD.","Phase 2 trial of bosakitug (anti-TSLP mAb) in AD dosing; top line expected H2 2026.","Roland Kolbeck appointed CSO replacing Joe Monahan (planned retirement through Q1 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":3232000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138356,"accession_number":"0001558370-25-009739","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aclaris ATI-2138 Phase 2a AD trial meets primary and key secondary endpoints; 60.5% mean EASI improvement at week 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14 patients enrolled; 10 per protocol; no SAEs or discontinuations; well tolerated with mild, transient TRAEs.","Mean EASI improvement 60.5% (77.1% excluding one outlier); 62.5% achieved ≥4-point itch reduction at week 12.","PD data show near-complete ITK target occupancy and downregulation of Th2, Th1/Th17, and fibrosis markers.","Company plans to further develop ATI-2138 in alopecia areata and explore other indications.","Preclinical work ongoing for next-gen ITK inhibitors; new INDs expected starting 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155806,"accession_number":"0001558370-25-008984","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics posts updated corporate presentation; no material changes discernible","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation includes corporate strategy and pipeline overview; no financial results or guidance changes disclosed.","No other material events or financial updates reported in the 8-K filing.","The presentation is available on the company's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155805,"accession_number":"0001558370-25-008430","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Aclaris shareholders approve doubling authorized shares to 400M and new equity plan with 25.6M reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 200M to 400M via Certificate of Amendment effective June 5, 2025; approved by ~96% of votes.","2025 Equity Incentive Plan approved with 25,556,247 share reserve (9M new shares plus rollover from prior plan).","Directors elected: Neal Walker (71.9M for), Andrew Schiff (71.7M for), William Humphries (56.7M for, 15.99M withheld).","Advisory vote on named executive officer compensation passed 55.5M to 16.98M; PwC ratified as auditor for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155804,"accession_number":"0001558370-25-006851","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aclaris reports Q1 net loss $15.1M, cash runway extended to H1 2028; multiple pipeline milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $15.1M vs $16.9M YoY; revenue $1.5M vs $2.4M; cash $190.5M as of March 31, 2025.","Cash runway extended through first half of 2028, fully funding preclinical and clinical plans.","Bosakitug Phase 2 in atopic dermatitis to start Q2 2025; seeking partners for respiratory indications.","ATI-2138 Phase 2a AD top line results expected June 2025; ATI-052 IND cleared, Phase 1 starting Q2 2025.","Jesse W. Hall appointed CMO; Sun Pharma injunction lifted, offering potential non-dilutive financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":1455000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174275,"accession_number":"0001558370-25-001679","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q4 net loss $96.6M, revenue $9.2M; cash $203.9M; pipeline catalysts in H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $96.6M in Q4 2024 vs $1.5M in Q4 2023; included $86.9M in-process R&D charge from bosakitug license.","Revenue $9.2M in Q4 2024 vs $17.6M in Q4 2023; full year revenue $18.7M vs $31.2M.","Cash, equivalents and marketable securities $203.9M at Dec 31, 2024; cash runway expected into 2028.","Phase 2 data from partner CTTQ in severe asthma and CRSwNP expected H1 2025; Phase 2b for bosakitug in AD enrollment H1 2025.","Leadership changes: Neal Walker named CEO; Hugh Davis appointed President and COO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":18720000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174274,"accession_number":"0001558370-25-000148","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics updates corporate presentation; no material new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an updated investor presentation on January 13, 2025.","Presentation content not fully available in this filing for review.","Routine update; no earnings, pipeline, or financial guidance changes announced.","Presentation available on Aclaris website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191220,"accession_number":"0001558370-24-015838","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Aclaris licenses anti-TSLP/IL4R biologics, raises $80M, appoints Davis as President/COO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License deal: $30M upfront, $4.5M dev reimbursement, warrants for 14.3M shares at $0.00001, up to $920M milestones, royalties.","Private placement: 35.6M shares at $2.25 for $80M gross; closed Nov 19; led by Vivo Capital; cash runway into 2028.","Leadership additions: Hugh Davis as President/COO + Class III director; Steven Knapp EVP Regulatory & Quality.","Adopted 2024 Inducement Plan reserving 2M shares; Davis granted options for 375K shares, RSU for 107K shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191219,"accession_number":"0001558370-24-014522","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Therapeutics reports Q3 net loss $7.6M, improved from $29.3M YoY; cash into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.6M vs $29.3M in Q3 2023; revenue fell to $4.3M from $9.3M.","R&D expenses dropped to $6.0M from $23.9M, driven by reduced clinical and manufacturing costs.","Cash, equivalents and marketable securities of $173.4M expected to fund operations into 2028.","First patient dosed in Phase 2a trial of ATI-2138 for atopic dermatitis; top-line data expected H1 2025.","Seeking global development partner for lepzacitinib (ATI-1777) after positive Phase 2b in atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":9509000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207683,"accession_number":"0001558370-24-011201","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q2 net loss narrows to $11.0M; cash runway extended into 2028 via $26.5M royalty sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.8M (+47% YoY) driven by higher Lilly royalties; net loss $11.0M vs $29.6M.","Cash, equivalents and securities $149.9M; July 2024 received $26.5M upfront from OLUMIANT royalty sale.","Phase 2a trial of ATI-2138 in atopic dermatitis initiated; enrollment expected in coming weeks.","Seeking global partner for lepzacitinib (ATI-1777) after positive Phase 2b top-line results.","R&D expense fell 65% to $8.8M due to completion of several clinical trials and headcount reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":5163000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207682,"accession_number":"0001558370-24-009853","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aclaris sells OLUMIANT royalties to OMERS for up to $31.5M upfront and milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $26.5M upfront; eligible for up to $5M additional based on 2024 sales milestones for OLUMIANT.","Sold portion of future OLUMIANT royalties from Lilly and 100% of remaining anniversary milestone payments.","Non-dilutive transaction; proceeds to strengthen balance sheet and support strategic priorities.","Aclaris continues strategic review; will invest in internal immuno-inflammatory pipeline programs.","OLUMIANT (baricitinib) is Lilly's treatment for alopecia areata; royalty term runs through remainder of license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225152,"accession_number":"0001558370-24-009009","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclaris shareholders elect two directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Christopher Molineaux (29.2M for, 16.2M withheld) and Vincent Milano (42.3M for, 3.1M withheld) as directors.","Advisory vote on executive compensation approved: 29.0M for, 16.3M against, 21k abstain, with 12.5M broker non-votes.","Ratified PricewaterhouseCoopers as auditor for FY2024: 56.6M for, 1.2M against, 23k abstain.","Turnout of 81.09% (57.8M of 71.3M shares outstanding) present or represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225151,"accession_number":"0001558370-24-007055","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.","Cash and marketable securities $161.4M at March 31, 2024; expects lower quarterly cash burn ahead.","Progressing ATI-2138 (ITK/JAK3 inhibitor) into Phase 2a proof-of-concept trial for moderate-to-severe atopic dermatitis.","Seeking global development partner for lepzacitinib (topical JAK 1/3 inhibitor) after positive Phase 2b AD data.","R&D expenses fell to $9.8M from $22.6M, driven by wind-down of programs and workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":2398000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244379,"accession_number":"0001558370-24-003572","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Aclaris directors to depart at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Andrew Powell resigns effective June 6, 2024; no disagreement cited.","Director Bryan Reasons will not stand for re-election at June 6 annual meeting; no disagreement.","No replacements announced for the two departing board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244378,"accession_number":"0001558370-24-001752","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.","Full-year net loss $88.5M; cash & securities $181.9M (Dec 2023) vs $229.8M (Dec 2022).","Impairment charge of $6.6M on IPR&D asset after discontinuing an immuno-inflammatory drug candidate.","Positive Phase 2b top-line for ATI-1777 in atopic dermatitis; seeking a partner for development/commercialization.","Co-founder Dr. Neal Walker returns as Interim CEO; company to advance zunsemetinib in oncology via Washington University trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":31249000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244377,"accession_number":"0001558370-24-000769","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris terminates CMO, enters separation with former CEO; promotes CSO to full-time","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated Gail Cawkwell as CMO effective Jan 31, 2024, without cause; receives 12-month salary continuation and COBRA coverage.","Entered separation agreement with former CEO Douglas Manion on Feb 4, 2024; receives 12-month salary continuation plus unpaid 2023 bonus.","Amended CSO Joseph Monahan's employment; base salary raised to $430,000, moves from part-time to full-time effective Feb 1, 2024.","Monahan’s new agreement has a 2-year initial term with automatic one-year renewals unless 90-day notice is given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244375,"accession_number":"0001558370-24-000770","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K/A","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris discloses interim CEO Neal Walker's compensation: $500k salary, equity awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Manion stepped down as CEO/President effective Jan 16, 2024; no disagreement.","Neal Walker appointed Interim CEO; receives $500,000 base salary, bonus eligible at 60% of base.","Granted stock option for 497,000 shares at $1.20 per share, vesting monthly over 15 months.","Also granted RSU for 142,000 shares with same 15-month monthly vesting and change-in-control acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}